ILC Therapeutics

Executive Summary

ILC Therapeutics is a UK-based biotechnology company pioneering Hybrid Interferons, a novel class of engineered cytokines designed to improve therapeutic profiles and address diseases with significant unmet needs. Founded in 2016, the company's lead candidate, Alfacyte, is a broad-spectrum antiviral being developed primarily for respiratory syncytial virus (RSV), a leading cause of respiratory infections in infants and the elderly with no approved vaccine or effective therapy. Alfacyte leverages the company's proprietary hybrid interferon technology to enhance antiviral activity while reducing toxicity, potentially offering a best-in-class treatment option. The RSV market represents a substantial opportunity, with global incidence and high unmet need driving interest from larger pharmaceutical partners. The company's platform extends beyond RSV, with potential applications across other viral infections and oncology indications. ILC Therapeutics remains in a relatively early stage, with Alfacyte likely in preclinical or early clinical development. Key milestones include the initiation of first-in-human trials and validation of the hybrid interferon approach. While the technology is promising, risks include the challenges of clinical development, regulatory hurdles, and the need for further funding. With a focused strategy and a differentiated platform, ILC Therapeutics has potential to capture value in the antiviral space, though investors should monitor upcoming clinical catalysts and partnership activities.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 Clinical Trial for Alfacyte in RSV70% success
• Q4 2026Preclinical Data Update for Hybrid Interferon Platform in Other Indications50% success
• H1 2027Strategic Partnership or Licensing Agreement for Alfacyte30% success